TD Cowen analyst Ryan Langston has maintained their bullish stance on UNH stock, giving a Buy rating today.
Ryan Langston has given his Buy rating due to a combination of factors, despite the recent challenges faced by UnitedHealth. The company has experienced some setbacks, including a reduction in earnings per share estimates for 2025 and 2026, primarily due to unexpected trends in Medicare Advantage and lower-than-expected coding in Optum Health. However, Langston anticipates a recovery in margins by 2026, supported by favorable rate adjustments and improved coding trends.
Moreover, while the revenue outlook for Optum Health has been adjusted downward, UnitedHealth’s consolidated revenue guidance remains strong, with UHC and Rx segments performing above initial expectations. Management is optimistic about addressing current issues within the year, which could lead to stronger performance in 2026 and a return to the company’s long-term earnings growth trajectory. These factors contribute to Langston’s confidence in UnitedHealth’s potential for future growth, justifying the Buy rating.
In another report released today, KeyBanc also maintained a Buy rating on the stock with a $575.00 price target.